Skip to main content
Clinical Trials/NCT02337465
NCT02337465CompletedNot Applicable

Integrated 3D X-ray and Ultrasound Guided Radiation Therapy of Soft Tissue Targets

Case Comprehensive Cancer Center1 site in 1 country30 target enrollmentStarted: September 22, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
30
Locations
1
Primary Endpoint
Number of Participants Able to Have the Ultrasound Probe Attached During the Entire Treatment Course

Study Overview

Brief Summary

This clinical trial studies if kilo-voltage cone beam computed tomography (KV-CBCT) and ultrasound imaging works in guiding radiation therapy in patients with prostate, liver, or pancreatic cancer. Computer systems, such as KV-CBCT and ultrasound imaging, allow doctors to create a 3-dimensional picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed.

Detailed Description

PRIMARY OBJECTIVES:

I. To investigate the feasibility of combining on-board cone beam computed tomography (CBCT) with ultrasound imaging to overcome the shortcomings of CBCT or ultrasound imaging alone for imaging guided radiotherapy delivery.

OUTLINE:

Patients undergo ultrasound imaging prior to and during radiation therapy. Patients also undergo kilo-voltage cone beam computed tomography prior to radiation therapy.

Update (2021/02/04): Removed secondary outcome "Incidence of Adverse Events Related to the Ultrasound Probe". Per PI: Study initially intended to involve a non-FDA approved probe for use with liver patients but removed this section.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
19 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The patient must have either 1) cancer involving the liver by biopsy or radiographic criteria, or 2) prostate cancer by biopsy, with the intent of undergoing definitive dose radiation therapy to targets within the liver, or prostate. Patients with prostatectomy receiving post-operative radiotherapy are also eligible.
  • •Karnofsky performance status (PS) ≥ 70
  • •Subjects must have the ability to understand and the willingness to sign a written informational form

Exclusion Criteria

  • •Patients with uncontrolled inter-current illness or psychiatric illness/social situations that would limit compliance with study requirements

Arms & Interventions

Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)

Experimental

Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.

Intervention: Cone-Beam Computed Tomography (Device)

Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)

Experimental

Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.

Intervention: 3-Dimensional Ultrasound-Guided Radiation Therapy (Radiation)

Outcomes

Primary Outcomes

Number of Participants Able to Have the Ultrasound Probe Attached During the Entire Treatment Course

Time Frame: Up to 1 year

Proportion of participants able to have the ultrasound probe attached during the entire treatment course

Percentage of Ultrasound Images Which Are Clinically Adequate for Treatment Set-up

Time Frame: Up to 1 year

Percentage of ultrasound images which are clinically adequate for treatment set-up in the judgment of the treating physician

Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound Probe

Time Frame: Up to 1 year

Quality of plans for patients not affected in the presence of the ultrasound probe, defined as no more than a 2% decrease in tumor coverage, and also no more than a 2% increase in the dose to the most critical normal tissue for that tumor location

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials